Humana (NYSE:HUM) Given New $370.00 Price Target at Oppenheimer

Humana (NYSE:HUM) had its price objective decreased by equities research analysts at Oppenheimer from $415.00 to $370.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the insurance provider’s stock. Oppenheimer’s target price would indicate a potential upside of 17.07% from the company’s current price.

A number of other equities analysts have also recently commented on the stock. UBS Group reissued a “neutral” rating and issued a $370.00 price target (down previously from $530.00) on shares of Humana in a research note on Friday, January 26th. Barclays cut their price objective on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Mizuho cut their price objective on shares of Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Bank of America reaffirmed a “neutral” rating and issued a $342.00 price objective (down previously from $470.00) on shares of Humana in a research note on Tuesday, April 2nd. Finally, Argus cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $440.95.

Humana Price Performance

HUM stock opened at $316.04 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. Humana has a one year low of $299.23 and a one year high of $541.21. The stock has a market cap of $38.13 billion, a PE ratio of 15.95, a P/E/G ratio of 1.92 and a beta of 0.45. The firm has a 50 day simple moving average of $329.24 and a two-hundred day simple moving average of $396.94.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 2.34% and a return on equity of 19.44%. The business had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the previous year, the company earned $9.38 EPS. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Humana will post 16.06 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Morgan Stanley increased its stake in shares of Humana by 6.2% in the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock worth $992,938,000 after acquiring an additional 119,760 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after acquiring an additional 402,559 shares in the last quarter. Norges Bank bought a new position in shares of Humana in the 4th quarter worth about $676,800,000. Northern Trust Corp increased its stake in shares of Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock worth $645,850,000 after acquiring an additional 64,245 shares in the last quarter. Finally, Sanders Capital LLC bought a new position in shares of Humana in the 4th quarter worth about $489,300,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.